Published in Am J Transplant on December 01, 2004
Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol (2010) 1.08
Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics (2012) 0.97
Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol (2008) 0.95
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol (2013) 0.87
Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience. Clin Exp Nephrol (2009) 0.81
Cardiovascular risk factors following renal transplant. World J Transplant (2015) 0.75
Another cause for the same old problem. Am J Transplant (2004) 0.75
Efficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study. Indian J Nephrol (2017) 0.75
Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism. PLoS One (2014) 0.75
Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant. World J Transplant (2017) 0.75
Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients. Br J Clin Pharmacol (2005) 0.75
Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. Biomed Res Int (2017) 0.75
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
Impact of navigators on completion of steps in the kidney transplant process: a randomized, controlled trial. Clin J Am Soc Nephrol (2012) 2.30
Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation (2007) 2.18
Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant (2005) 1.60
Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation (2002) 1.52
Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation (2007) 1.50
Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation (2012) 1.48
Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant (2003) 1.47
Use of sirolimus in solid organ transplantation. Drugs (2007) 1.40
Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant (2002) 1.38
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression. Transpl Int (2008) 1.37
Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol (2005) 1.37
Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol (2004) 1.22
New-onset diabetes mellitus after solid organ transplantation. Transpl Int (2008) 1.22
Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation (2008) 1.11
Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transplant (2002) 1.06
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation (2002) 1.04
Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant (2003) 1.04
Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation (2010) 1.02
Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol (2007) 0.99
Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol (2006) 0.97
Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery (2008) 0.95
Inhibition of nitric oxide synthase reduces renal ischemia/reperfusion injury. J Surg Res (2005) 0.91
An aggressive surgical approach is warranted in the management of cystic pancreatic neoplasms. Am J Surg (2007) 0.89
Heterogeneous alterations in human alloimmunity associated with immunization. Transplantation (2005) 0.89
Primary squamous cell carcinoma of the main hepatic bile duct. Can J Surg (2008) 0.88
Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation (2004) 0.87
Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation (2003) 0.87
Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination. Perit Dial Int (2002) 0.87
Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant (2005) 0.86
Immune factors influencing ethnic disparities in kidney transplantation outcomes. Expert Rev Clin Immunol (2011) 0.85
Pancreas after kidney transplantation. J Am Soc Nephrol (2002) 0.85
Pancreatic resection in octogenarians. J Surg Res (2009) 0.85
Management of the kidney transplant recipient. Prim Care (2008) 0.83
Determinants of quality of life changes among long-term cardiac transplant survivors: results from longitudinal data. J Heart Lung Transplant (2003) 0.83
Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation (2006) 0.83
Transplant: immunology and treatment of rejection. Am J Kidney Dis (2004) 0.82
Effects of cellular sensitization and donor age on acute rejection and graft function after deceased-donor kidney transplantation. Transplantation (2013) 0.82
Induction antibody therapy in kidney transplantation. Am J Kidney Dis (2009) 0.81
Food protein sensitivity with partial villous atrophy after pediatric liver transplantation with tacrolimus immunosuppression. Pediatr Transplant (2006) 0.81
Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens (2007) 0.81
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant (2002) 0.81
Donor phosphorus levels and recipient outcomes in living-donor kidney transplantation. Clin J Am Soc Nephrol (2011) 0.81
Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation (2006) 0.80
T-cell immune monitoring by the ELISPOT assay for interferon gamma. Clin Chim Acta (2012) 0.80
Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant (2002) 0.79
Fever, infection, and rejection after kidney transplant failure. Transplantation (2014) 0.78
Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine. Transplantation (2002) 0.77
Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant (2003) 0.77
Posttransplant lymphoproliferative disorders: a continued threat for kidney transplant recipients. Am J Kidney Dis (2011) 0.77
Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation (2008) 0.76
Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma. Am J Surg (2008) 0.76
Fever, Infection, and Rejection After Kidney Transplant Failure. Transplantation (2013) 0.75
Anemia after kidney transplantation--is the incidence increasing? Am J Transplant (2003) 0.75
Steroid withdrawal for the (selected) masses. Am J Transplant (2005) 0.75
Anemia after kidney transplantation: time for action. J Am Soc Nephrol (2006) 0.75
Are maintenance corticosteroids no longer necessary after kidney transplantation? Clin J Am Soc Nephrol (2012) 0.75
Reducing exposure to calcineurin inhibitors after kidney transplantation. Am J Kidney Dis (2008) 0.75
The Utility of Screening Colonoscopy During Kidney Transplant Evaluation. Exp Clin Transplant (2017) 0.75
In the literature: cancer incidence before and after kidney transplantation. Am J Kidney Dis (2007) 0.75
Transplantation of Renal Allograft After Removal of Renal Cell Carcinoma: Case Report and Review of the Literature. Exp Clin Transplant (2019) 0.75
Refining the definition and management of high-risk organ transplant recipients. Curr Opin Organ Transplant (2009) 0.75
The 2010 nephrology quiz and questionnaire: part 1. Clin J Am Soc Nephrol (2011) 0.75